CML With Mutant ASXL1 Showed Decreased Sensitivity to TKI Treatment via Upregulation of the ALOX5-BLTR Signaling...

Area of Science:

• Hematology
• Molecular Biology
• Cancer Research

Background:

• Tyrosine kinase inhibitors (TKIs) have improved chronic myeloid leukemia (CML) outcomes.
• However, TKI resistance remains a challenge in CML treatment.
• Mutations in epigenome-related genes, like ASXL1, are linked to poor prognosis in CML, but mechanisms are unclear.

Purpose of the Study:

• To investigate the mechanisms of TKI resistance in CML associated with ASXL1 mutations.
• To identify downstream targets of mutated ASXL1 contributing to TKI resistance.

Main Methods:

• Utilized CML cell lines with conditional ASXL1 expression.
• Performed RNA microarray analysis to identify upregulated genes.
• Investigated the role of ALOX5 using gene expression and knockout models.
• Assessed TKI sensitivity and AKT phosphorylation following ALOX5 inhibition.

Main Results:

• Mutated ASXL1 reduced TKI sensitivity in CML cells.
• Arachidonate 5-lipoxygenase (ALOX5) was significantly upregulated by mutated ASXL1.
• Enforced ALOX5 expression induced TKI resistance; ALOX5 knockout increased sensitivity.
• Inhibition of ALOX5 downstream signaling suppressed AKT phosphorylation and enhanced TKI sensitivity.

Conclusions:

• TKI resistance in CML with ASXL1 mutations is mediated by ALOX5 overexpression.
• ASXL1 mutations may promote clonal advantage via AKT pathway activation through ALOX5.
• The ALOX5-BLTR signaling pathway represents a novel therapeutic target for CML patients with ASXL1 mutations.